EBS
Emergent Biosolutions Inc
6.70$
-1.3%
vs. previous close
Closing price · As of: Sep 23, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 37.6% | 37.0% | 37.8% | 43.2% | 44.8% | 42.9% | 49.6% | 50.8% | 53.9% | 50.2% | 48.3% | 59.6% | |
| 4.6% | 6.1% | 4.4% | 4.6% | 10.1% | 7.6% | 10.5% | 19.1% | 16.8% | 15.6% | 12.1% | 12.5% | |
| 4.6% | 6.1% | 4.4% | 4.6% | 10.1% | 7.6% | 10.5% | 19.1% | 16.8% | 15.6% | 12.1% | 12.5% | |
| 11.4% | 10.4% | 12.9% | 13.0% | 8.2% | 11.1% | 14.3% | 5.6% | 10.2% | 6.4% | 9.2% | 17.0% | |
| 18.7% | 17.9% | 18.5% | 21.0% | 21.8% | 22.3% | 22.0% | 23.9% | 24.4% | 26.0% | 24.8% | 27.2% | |
| 21.8% | – | – | – | 19.7% | 20.2% | 16.0% | 15.8% | 14.9% | 16.4% | – | – | |
| 11.5% | 0.0% | – | – | 0.0% | – | – | – | – | – | – | – | |
| 30.8% | 30.9% | 30.5% | 35.3% | 35.0% | 35.9% | 34.0% | 33.1% | 31.0% | 33.1% | 35.6% | 23.4% | |
| 63.2% | 64.6% | 63.2% | 74.5% | 65.6% | 65.4% | 61.2% | 62.2% | 60.1% | 60.4% | 60.4% | 69.4% | |
| 35.1% | 35.5% | 34.9% | 40.9% | 15.6% | 11.6% | 7.8% | 9.0% | 9.3% | 10.0% | 11.3% | 11.0% | |
| 22.0% | 22.7% | 25.6% | 27.6% | 0.2% | 0.2% | 0.0% | 0.1% | 0.0% | 0.0% | – | – | |
| 6.0% | 6.1% | 5.6% | 6.3% | 5.6% | 4.4% | 4.1% | 4.5% | 3.9% | 4.2% | 3.0% | 4.5% | |
| 23.7% | 24.3% | 24.8% | 29.5% | 44.8% | 47.5% | 46.7% | 47.1% | 45.4% | 43.4% | 43.4% | 52.1% | |
| 36.8% | 35.4% | 36.8% | 25.5% | 34.4% | 34.6% | 38.8% | 37.8% | 39.9% | 39.6% | 39.6% | 30.6% | |
| 1.5% | -1.2% | -0.7% | -19.6% | -12.3% | -15.2% | -10.1% | -11.0% | -7.2% | -12.1% | -11.6% | -29.8% | |
| 2.7% | 2.8% | 2.9% | 3.5% | 3.8% | 3.9% | 4.0% | 3.8% | 3.9% | 4.0% | 4.3% | 4.6% |
Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.